Photodynamic therapy for the management of laryngeal malignancies

Merrill A. Biel

Research output: Chapter in Book/Report/Conference proceedingChapter


Carcinoma of the larynx accounts for 25-30% of all carcinomas of the head and neck [1]. Early carcinomas of the larynx (Cis, T1, T2) and severe dysplasia are presently treated with either radiation therapy or surgery alone. Five-year cure rates achieved with this therapy is 75-90%. Radiation therapy has the advantage of preserving the physical integrity of the larynx, thereby preserving the voice. Radiation therapy, however, has significant disadvantages even when small laryngeal fields of radiation are used. These disadvantages include discomfort and mucositis during and for potential prolonged periods after therapy, permanently altered voice quality, dysphagia, chondroradionecrosis of the larynx and trachea, and the extensive length of therapy (6-7 weeks) [2, 3]. Surgical therapy for early carcinomas, that is, T1 and T2, of the larynx includes performing a partial cordectomy or hemilaryngectomy. Although cure rates are high, surgical removal of portions of the vocal cord or hemilarynx results in significant alteration of the quality of voice [4].

Original languageEnglish (US)
Title of host publicationBiomedical Optics in Otorhinolaryngology
Subtitle of host publicationHead and Neck Surgery
PublisherSpringer New York
Number of pages10
ISBN (Electronic)9781493917587
ISBN (Print)9781493917570
StatePublished - Jan 1 2016


  • Carcinoma in situ
  • Early vocal cord cancer
  • Larynx cancer
  • Photodynamic therapy


Dive into the research topics of 'Photodynamic therapy for the management of laryngeal malignancies'. Together they form a unique fingerprint.

Cite this